Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Effect of CagriSema on bone biomarkers in participants with inadequately controlled type 2 diabetes: REIMAGINE 2​

Authors :

Martin Haluzík1; Therese Wilbek Fabricius2; Reena Gajria2; Sathish Manogaran3; Marco Ponzetti2; João Eurico Fonseca4

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
Diabetes
Congress short oral presentation
Amylin
CagriSema
PHASE 3 (RCT)